Literature DB >> 24697910

Effect of focal lamina cribrosa defect on glaucomatous visual field progression.

Omar S Faridi1, Sung Chul Park2, Rajiv Kabadi3, Daniel Su1, Carlos Gustavo De Moraes4, Jeffrey M Liebmann4, Robert Ritch5.   

Abstract

OBJECTIVE: To evaluate the association between focal, structural defects of the lamina cribrosa (LC) and glaucomatous visual field (VF) progression.
DESIGN: Retrospective, observational study. PARTICIPANTS: A total of 169 patients with glaucoma (169 eyes) with a range of glaucomatous damage.
METHODS: Serial horizontal and vertical enhanced-depth imaging optical coherence tomography (EDI OCT) B-scans of the optic nerve head were obtained from patients with glaucoma with 5 or more prior Humphrey 24-2 VFs (Carl Zeiss Meditec, Inc, Dublin, CA). The EDI OCT scans were reviewed for the presence of focal LC defects (laminar holes or disinsertions with a diameter >100 μm). The VF progression was defined as having ≥ 2 significantly progressing test points (with a slope calculated using pointwise linear regression [PLR], worse than -1.0 dB/year at P<0.01). Age, intraocular pressure (IOP), baseline VF mean deviation (MD), disc hemorrhage, and central corneal thickness (CCT) were recorded. MAIN OUTCOME MEASURES: The relationship between focal LC defects and the rate and risk of VF progression.
RESULTS: Mean age and VF MD at the time of EDI OCT were 69 ± 12 years and -11.49 ± 6.87 dB, respectively. Sixty eyes (36%) progressed according to PLR criteria. Progression was more common in eyes with, rather than without, focal LC defects (38/81 eyes [47%] vs. 22/88 eyes [25%], P = 0.003). Among the evaluated parameters, the presence of focal LC defects, disc hemorrhage, higher mean follow-up IOP, greater number of VFs, and longer follow-up period were significantly associated with VF progression in the multivariable analyses (odds ratios, 2.90, 4.66, 1.22, 1.25, and 1.27, respectively; P = 0.010, P = 0.002, P = 0.002, P<0.001, and P<0.001, respectively). The mean global progression rate was significantly faster in the group with focal LC defect than in the group with no focal LC defect (-0.54 ± 0.99 dB/year vs. -0.28 ± 0.52 dB/year; P = 0.031). Among the 60 progressing eyes, despite no significant difference in the mean number of progressing VF points per eye (6.7 ± 7.0 vs. 6.5 ± 4.4; P = 0.899), the mean localized progression rate was significantly faster in the eyes with focal LC defects than in the eyes with no focal LC defects (-2.85 ± 1.85 dB/year vs. -1.75 ± 0.56 dB/year; P = 0.009).
CONCLUSIONS: Focal LC defects are strongly associated with glaucomatous VF progression, and eyes with focal LC defects tend to progress faster than those without.
Copyright © 2014 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2014        PMID: 24697910     DOI: 10.1016/j.ophtha.2014.02.017

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  38 in total

Review 1.  In vivo imaging methods to assess glaucomatous optic neuropathy.

Authors:  Brad Fortune
Journal:  Exp Eye Res       Date:  2015-06-03       Impact factor: 3.467

2.  Association Between Lamina Cribrosa Defects and Progressive Retinal Nerve Fiber Layer Loss in Glaucoma.

Authors:  Sasan Moghimi; Linda M Zangwill; Patricia Isabel C Manalastas; Min Hee Suh; Rafaella C Penteado; Huiyuan Hou; Kyle Hasenstab; Elham Ghahari; Christopher Bowd; Robert N Weinreb
Journal:  JAMA Ophthalmol       Date:  2019-04-01       Impact factor: 7.389

3.  Optic nerve compression: the role of the lamina cribrosa and translaminar pressure.

Authors:  Mario R Romano; Gilda Cennamo; Maria Angelica Breve; Michela Piedepalumbo; Claudio Iovino; Nunzio Velotti; Giovanni Cennamo
Journal:  Int J Ophthalmol       Date:  2017-12-18       Impact factor: 1.779

4.  Deep learning based noise reduction method for automatic 3D segmentation of the anterior of lamina cribrosa in optical coherence tomography volumetric scans.

Authors:  Zaixing Mao; Atsuya Miki; Song Mei; Ying Dong; Kazuichi Maruyama; Ryo Kawasaki; Shinichi Usui; Kenji Matsushita; Kohji Nishida; Kinpui Chan
Journal:  Biomed Opt Express       Date:  2019-10-21       Impact factor: 3.732

5.  The impact of disc hemorrhage studies on our understanding of glaucoma: a systematic review 50 years after the rediscovery of disc hemorrhage.

Authors:  Tetsuya Yamamoto
Journal:  Jpn J Ophthalmol       Date:  2018-11-21       Impact factor: 2.447

6.  Optical Coherence Tomography Angiography Vessel Density in Glaucomatous Eyes with Focal Lamina Cribrosa Defects.

Authors:  Min Hee Suh; Linda M Zangwill; Patricia Isabel C Manalastas; Akram Belghith; Adeleh Yarmohammadi; Felipe A Medeiros; Alberto Diniz-Filho; Luke J Saunders; Siamak Yousefi; Robert N Weinreb
Journal:  Ophthalmology       Date:  2016-08-31       Impact factor: 12.079

7.  Lamina Cribrosa in Glaucoma: Diagnosis and Monitoring.

Authors:  Ricardo Y Abe; Carolina P B Gracitelli; Alberto Diniz-Filho; Andrew J Tatham; Felipe A Medeiros
Journal:  Curr Ophthalmol Rep       Date:  2015-06-01

8.  Deep Retinal Layer Microvasculature Dropout Detected by the Optical Coherence Tomography Angiography in Glaucoma.

Authors:  Min Hee Suh; Linda M Zangwill; Patricia Isabel C Manalastas; Akram Belghith; Adeleh Yarmohammadi; Felipe A Medeiros; Alberto Diniz-Filho; Luke J Saunders; Robert N Weinreb
Journal:  Ophthalmology       Date:  2016-10-18       Impact factor: 12.079

9.  Disc Hemorrhages Are Associated With the Presence and Progression of Glaucomatous Central Visual Field Defects.

Authors:  Aakriti G Shukla; Portia E Sirinek; C Gustavo De Moraes; Dana M Blumberg; George A Cioffi; Alon Skaat; Christopher A Girkin; Robert N Weinreb; Linda M Zangwill; Donald C Hood; Jeffrey M Liebmann
Journal:  J Glaucoma       Date:  2020-06       Impact factor: 2.503

10.  Measurement of lamina and prelaminar thicknesses of both eyes in patients with unilateral branch retinal vein occlusion.

Authors:  Yengwoo Son; Seungwoo Lee; Jongyeop Park
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-09-14       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.